Managing hereditary ovarian cancer

Maturitas

Volumn 64, Issue 3, 2009, Pages 172-176

  Mourits, M J ^a   de Bock, G H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bilateral salpingo oophorectomy; BRCA1 gene; BRCA2 gene; Hereditary cancer syndrome; Ovarian neoplasms; Reproduction

Indexed keywords

CA 125 ANTIGEN; ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER RISK; CANCER SCREENING; FAMILIAL CANCER; GENE MUTATION; GYNECOLOGIC SURGERY; HUMAN; OVARY CANCER; PROPHYLAXIS; REVIEW; RISK REDUCTION; SALPINGOOOPHORECTOMY; TRANSVAGINAL ECHOGRAPHY;

ADULT; ANIMALS; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; OVARIAN NEOPLASMS; OVARIECTOMY; RISK FACTORS;

EID: 70350613211     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2009.09.009     Document Type: Review

References (61)

1. Claus E.B., Schildkraut J.M., Thompson W.D., and Risch N.J. The genetic attributable risk of breast and ovarian cancer. Cancer 77 (1996) 2318-2324
2. Boland C.R. Evolution of the nomenclature for the hereditary colorectal cancer syndromes. Fam Cancer 4 (2005) 211-218
3. Vasen H.F., Wijnen J.T., Menko F.H., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110 (1996) 1020-1027
4. Geary J., Sasieni P., Houlston R., et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7 (2008) 163-172
5. Chen S., and Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 (2007) 1329-1333
6. Watson P., and Lynch H.T. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71 (1993) 677-685
7. American College of Obstetricians and Gynecologists, ACOG Committee on Practice Bulletins-Gynecology, ACOG Committee on Genetics, and Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol 113 (2009) 957-966
8. Geomini P., Kruitwagen R., Bremer G.L., Cnossen J., and Mol B.W. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 113 (2009) 384-394
9. Sassone A.M., Timor-Tritsch I.E., Artner A., Wetshoff C., and Warren W.B. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol 78 (1991) 70-76
10. Muto M.G., Cramer D.W., Brown D.L., et al. Screening for ovarian cancer: the preliminary experience of a familial ovarian cancer center. Gynecol Oncol 51 (1993) 12-20
11. Oei A.L., Massuger L.F., Bulten J., Ligtenberg M.J., Hoogerbrugge N., and de Hullu J.A. Surveillance of women at high risk for hereditary ovarian cancer is inefficient. Br J Cancer 94 (2006) 814-819
12. Mourits M.J., Van der Velde N.M., Arts H.J., and De Bock G.H. High percentage of abnormal findings on TVU needs further discussion. Br J Cancer 95 (2006) 1125
13. Miller J.C., Horrowitz N.S., Thrall J.H., and Lee S.I. Evaluating adnexal lesions: which need follow-up?. J Am Coll Radiol 4 (2007) 725-729
14. Healy D.L., Bell R., Robertson D.M., et al. Ovarian status in healthy postmenopausal women. Menopause 15 (2008) 1109-1114
15. Valentin L., Skoog L., and Epstein E. Frequency and type of adnexal lesions in autopsy material in postmenopausal women: ultrasound study with histological correlation. Ultrasound Obstet Gynecol 22 (2003) 284-289
16. Bourne T.H., Campbell S., Reynolds K.M., et al. Screening for early ovarian cancer with transvaginal ultrasonography and colour Doppler blood flow imaging. Br Med J 306 (1993) 1025-1029
17. Ueland F.R., DePriest P.D., Pavlik E.J., Kryscio R.J., and van Nagell Jr. J.R. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol 91 (2003) 46-50
18. Kabawat S.E., Bast Jr. R.C., Bhan A.K., Welch W.R., Knapp R.C., and Colvin R.B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2 (1983) 275-285
19. Bast Jr. R.C., Klug T.L., St John E., et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309 (1983) 883-887
20. Mann W.J., Patsner B., Coher H., and Loesch M. Preoperative serum CA-125 levels in patients with surgical stage I invasive ovarian adenocarcinoma. J Natl Cancer Inst 80 (1998) 208-213
21. Jacobs I.J., and Bast Jr. R.C. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 4 (1989) 1-5
22. Bast Jr. R.C., Brewer M., Zou C., et al. Prevention and early detection of ovarian cancer: mission impossible?. Recent Results Cancer Res 174 (2007) 91-100
23. Jacobs I. Screening for familial ovarian cancer: the need for well-designed prospective studies. J Clin Oncol 23 (2005) 5443-5445
24. Greene M.H., Piedmonte M., Alberts D., et al. A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev 17 (2008) 594-604
25. Hannemann M., Fox R., and James M. Ovarian cancer death reduction for women at high risk: workload implications for gynaecology services. J Obstet Gynaecol 26 (2006) 42-44
26. Zhang Z., Yu Y., Xu F., et al. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol 107 (2007) 526-531
27. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 (2002) 572-577
28. Liu C., Shea N., Rucker S., et al. Proteomic patterns for classification of ovarian cancer and CTCL serum samples utilizing peak pairs indicative of post-translational modifications. Proteomics 7 (2007) 4045-4052
29. Nossov V., Amneus M., Su F., et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?. Am J Obstet Gynecol 199 (2008) 215-223
30. Van der Velde N.M., Mourits M.J., Arts H.J., et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. Int J Cancer 124 (2009) 919-923
31. Woodward E.R., Sleightholme H.V., Considine A.M., Williamson S., McHugo J.M., and Cruger D.G. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG 114 (2007) 1500-1509
32. Bosse K., Rhiem K., Wappenschmidt B., et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol 103 (2006) 1077-1082
33. Gaarenstroom K.N., Van der Hiel B., Tollenaar R.A.E.M., et al. Efficacy of screening at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16 (2006) 54-59
34. Olivier R.I., Lubsen-Brandsma M.A.C., Verhoef S., and Van Beurden M. CA125 and transvaginal ultrasound monitoring in high-risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol 100 (2006) 20-26
35. Vasen H.F.A., Tesfay E., Boonstra H., et al. Early detection of breast and ovarian cancer in families with BRCA mutations. Eur J Cancer 41 (2005) 549-554
36. Meeuwissen P.A.M., Seynaeve C., Brekelmans C.T.M., Meijers-Heijboer H.J., Klijn J.G.M., and Burger C.W. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97 (2005) 476-482
37. Stirling D., Evans D.G., Pichert G., et al. Screening for familial ovarian cancer failure of current protocols to detect ovarian cancer at an early stage according to the international federation of gynecology and obstetrics system. J Clin Oncol 23 (2005) 5588-5596
38. Laframboise S., Nedelcu R., Murphy J., Cole D.E.C., and Rosen B. Use of CA-125 and ultrasound in high-risk women. Int J Gynecol Cancer 12 (2002) 86-91
39. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (2002) 1260-1268
40. Dørum A., Heimdal K., Løvslett K., et al. Prospectively detected cancer in familial breast/ovarian cancer screening. Acta Obstet Gynecol Scand 78 (1999) 906-911
41. Evans G.R., Gaarenstroom K.N., Stirling D., et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet (2008) [Epub ahead of print]
42. Goff B.A., Mandel L.S., Melancon C.H., and Muntz H.G. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 291 (2004) 2705-2712
43. Lowe K.A., Andersen M.R., Urban N., Paley P., Dresher C.W., and Goff B.A. The temporal stability of the Symptom Index among women at high-risk for ovarian cancer. Gynecol Oncol (2009) [Epub ahead of print]
44. Menon U., Gentry-Maharaj A., Hallett R., et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 10 (2009) 327-340
45. Jacobs I.J., Skates S.J., MacDonald N., et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353 (1999) 1207-1210
46. Rebbeck T.R., Kauff N.D., and Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101 (2009) 80-87
47. Meijers-Heijboer H., Brekelmans C.T., Menke-Pluymers M., et al. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation. J Clin Oncol 21 (2003) 1675-1681
48. Bermejo-Pérez M.J., Márquez-Calderón S., and Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer 121 (2007) 225-231
49. Pal T., Permuth-Wey J., Kumar A., and Sellers T.A. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterisation of mismatch repair deficient tumor histology. Clin Cancer Res 14 (2008) 6847-6854
50. Mourits M.J., De Hullu J.A., Van Der Zee A.G., and Hollema H. Letter commenting on "Patholologic finding in prophylactic oophorectomy specimens in high-risk women" (87:52-6) by Pamela Paley, et al. Gynecol Oncol 93 (2004) 571
51. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347 (1996) 1713-1727
52. Brohet R.M., Goldgar D.E., Eastom D.F., et al. Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON and the IBCCS Collaboration Group. J Clin Oncol 25 (2007) 3831-3836
53. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V., Doll R., Hermon C., Peto R., and Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371 (2008) 303-314
54. Antoniou A.C., Rookus M., Andrieu N., et al. Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carriers Cohort Study. Cancer Epidemiol Biomarkers Prev 18 (2009) 601-610
55. Kuliev A., and Verlinsky Y. Place of preimplantation diagnosis in genetic practice. Am J Med Genet A 134A (2005) 105-110
56. Madalinska J.B., Hollenstein J., Bleiker E., et al. Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 23 (2005) 6890-6898
57. Madalinska J.B., van Beurden M., Bleiker E.M., et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24 (2006) 3576-3582
58. Holmberg L., Iversen O.E., Rudenstam C.M., et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst 100 (2008) 475-482
59. Kenemans P., Bundred N.J., Foidart J.M., et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 10 (2009) 135-146
60. Von Schoultz E., and Rutqvist L.E. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 97 (2005) 533-535
61. Buijs C., Mom C.H., Willemse P.H., et al. Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 115 (2009) 573-580